Loading organizations...

§ Public · La Jolla, CA, USA
Turnstone Biologics is a technology company.
Turnstone Biologics is a clinical-stage biotechnology company focused on developing a differentiated approach to treat and cure patients with solid tumors. The company employs a new class of targeted viral immunotherapies, leveraging oncolytic viruses to specifically target and destroy cancer cells while stimulating an anti-tumor immune response. Their platform aims to deliver novel therapeutic options for difficult-to-treat cancers.
The company was founded in 2014 by Brian Lichty, David Stojdl, and John Bell. Their insight was centered on harnessing the power of oncolytic viruses to create potent and selective cancer treatments, building on decades of research into viral oncology. This foundational understanding laid the groundwork for their therapeutic pipeline.
Turnstone Biologics aims to serve patients suffering from a range of solid tumor cancers, providing new avenues for treatment where current options may be limited. The company's long-term vision is to transform patient care by delivering effective and potentially curative medicines that significantly improve outcomes for individuals battling cancer.
Turnstone Biologics has raised $132.0M across 3 funding rounds.
Turnstone Biologics has raised $132.0M in total across 3 funding rounds.
Turnstone Biologics has raised $132.0M across 3 funding rounds. Most recently, it raised $80.0M Series D in July 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2021 | $80M Series D | Santhosh Palani, Phd, CFA, Point72 | KohFounders, Sofinnova Investments, VenBio Partners, Venrock, Versant Ventures, 404 BIO, Brace Pharma Capital, Caas Capital Management, Eventide Asset Management, F Prime Capital, JM Family Enterprises, Northleaf Capital Partners, OrbiMed, Ridgeback Capital Investments, Sectoral Asset Management, Sixty Degree Capital, Surveyor Capital, Takeda Ventures, Teralys Capital | Announced |
| Nov 1, 2016 | $41M Series B | OrbiMed, BEN Auspitz | KohFounders, Sofinnova Investments, VenBio Partners, Venrock, Versant Ventures, Facit | Announced |
| Oct 1, 2015 | $11M Series A | Versant Ventures | KohFounders, Sofinnova Investments, VenBio Partners, Venrock, Facit | Announced |
Turnstone Biologics is a clinical-stage biotechnology company developing oncolytic viral immunotherapies that activate anti-tumor T‑cell responses for cancer treatment. [1][2]
High-Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech/Healthcare Landscape
Quick Take & Future Outlook
If you’d like, I can pull specific details about Turnstone’s current pipeline assets, recent trial identifiers and status, or summarize its most recent SEC filings and financial position.
Turnstone Biologics has raised $132.0M in total across 3 funding rounds.
Turnstone Biologics's investors include Santhosh Palani, PhD, CFA, Point72, KohFounders, Sofinnova Investments, venBio, Venrock, Versant Ventures, 404 Bio, Brace Pharma Capital, CaaS Capital Management, Eventide Asset Management, F-Prime Capital.